Sangamo Therapeutics Announces Conference Call To Review SB-913 CHAMPIONS Study Data And Participation At Upcoming Investor Conferences
|
RICHMOND, Calif., Aug. 30, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will host a conference call on September 5th at 9:00 a.m. ET to discuss clinical data from the CHAMPIONS Study, the Company's Phase 1/2 trial evaluating SB-913 in vivo genome editing therapeutic candidate for MPS II. The call will follow the presentation of the data earlier that day at the 2018 Symposium of the Society for the Study of Inborn Errors of Metabolism in Athens, Greece. Sangamo also announced today that management will participate in the following healthcare investor conferences in September.
Sangamo's presentation is scheduled for 9:10 a.m. ET on Thursday, September 6th. The Wells Fargo presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.
Sangamo's presentation is scheduled for 3:25 p.m. BST on Wednesday, September 12th. Webcasting services are not provided at the Bank of America Merrill Lynch conference. SB-913 Conference Call Sangamo will host a conference call on September 5, 2018, at 9:00 a.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 8798741. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 8798741. About Sangamo Therapeutics Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-conference-call-to-review-sb-913-champions-study-data-and-participation-at-upcoming-investor-conferences-300704736.html SOURCE Sangamo Therapeutics, Inc. |
||
Company Codes: NASDAQ-NMS:SGMO |